Medulloblastoma recurrent

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
5 Unique IMPs
0 Commercial trials
Drug classes (ATC)
ATC code not specified 1
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
mTOR inhibitor 1 substance
Kinase inhibitor 1 substance
Topoisomerase II inhibitor 1 substance
Phase I/II: 1 Phase I (Other): 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase I/II

1 trial
  • Assistance Publique Hopitaux De Paris Academic
    AXITINIB; ETOPOSIDE
    2023-509585-38-00 1 country 2024 n=40
    Recruiting

Phase I (Other)

2 trials
  • Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus Academic
    ALLOGENIC BONE MARROW-DERIVED MESENCHYMAL STEM CELLS TRANSDUCED WITH ICOVIR-5, EX VIVO EXPANDED
    2022-502516-37-00 1 country 2021 n=12
    Ended
  • Instytut Pomnik Centrum Zdrowia Dziecka Academic
    7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE HYDROCHLORIDE; EVEROLIMUS
    2025-524031-39-00 1 country n=48
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus Academic 1 Phase I (Other) 0
Instytut Pomnik Centrum Zdrowia Dziecka Academic 1 Phase I (Other) 0
Assistance Publique Hopitaux De Paris Academic 1 Phase I/II 1
New trials by year
2021
1
2024
1
← All indication landscapes